PPM1D is a potential target for 17q gain in neuroblastoma

Cancer Research

Volumn 63, Issue 8, 2003, Pages 1876-1883

  Saito Ohara, Fumiko ^a,b   Imoto, Issei ^a,b   Inoue, Jun ^a,c   Hosoi, Hajime ^d   Nakagawara, Akira ^e   Sugimoto, Tohru ^d   Inazawa, Johji ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DNA;

AMPLICON; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CHROMOSOME 17Q; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA TRANSFECTION; DOWN REGULATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCUS; GENE TARGETING; GENETIC GAIN; HUMAN; HUMAN CELL; NEUROBLASTOMA; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION;

CELL DEATH; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; DOWN-REGULATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM PROTEINS; NEUROBLASTOMA; NUCLEIC ACID HYBRIDIZATION; PHOSPHOPROTEIN PHOSPHATASE; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0037446975     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Evans, A. E., Silber, J. H., Shpilsky, A., and D'Angio, G. J. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992 in a single institution. J. Clin. Oncol., 14: 2504-2510, 1996.
2. Cotterill, S. J., Pearson, A. D., Pritchard, J., Foot, A. B., Roald, B., Kohler, J. A., and Imeson, J. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group Survey 1982-1992. Eur. J. Cancer, 36: 901-908, 2000.
3. Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V., Castelberry, R. P., de Bernardi, B., Evans, A. E., Favrot, M., and Hedborg, F. Revision of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol., 11: 1466-1477, 1993.
4. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., and Hammond, D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med., 313: 1111-1116, 1985.
5. Caron, H., van Sluis, P., de Kraker, J., Bokkerink, J., Egeler, M., Laureys, G., Slater, R., Westerveld, A., Voute, P. A., and Versteeg, R. Allelic loss of chromosome 1p as predictor of unfavourable outcome in patients with neuroblastoma. N. Engl. J. Med., 334: 225-230, 1996.
6. Bown, N., Cotterill, S., Lastowska, M., O'Neill, S., Pearson, A. D., Plantaz, D., Meddeb, M., Danglot, G., Brinkschmidt, C., Christiansen, H., Laureys, G., and Speleman, F. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med., 340: 1954-1961, 1999.
7. Look, A. T., Hayes, F. A., Nitschke, R., McWilliams, N. B., and Green, A. A. Cellular DNA content as predictor of response to chemotherapy in infants with unresectable neuroblastoma. N. Engl. J. Med., 311: 231-235, 1984.
8. Bown, N. Neuroblastoma tumour genetics: clinical and biological aspects. J. Clin. Pathol. (Lond.), 54: 897-910, 2001.
9. Maris, J. M., and Matthay, K. K. Molecular biology of neuroblastoma. J. Clin. Oncol. (Lond.), 17: 2264-2279. 1999.
10. Plantaz, D., Mohapatra, G., Matthay, K. K., Pellarin, M., Seeger, R. C., and Feuerstein, B. G. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am. J. Pathol., 150: 81-89, 1997.
11. Vandesompele, J., Van Roy, N., Van Gele, M., Laureys, G., Ambros, P., Heimann, P., Devalck, C., Schuuring, E., Brock, P., Otten, J., Gyselinck, J., De Paepe, A., and Speleman, F. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer, 23: 141-152, 1998.
12. Lo Cunsolo, C., Bicocchi, M. P., Petti, A. R., and Tonini, G. P. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status. Br. J. Cancer. 83: 1295-1300, 2000.
13. Fukuda, Y., Kurihara, N., Imoto, I., Yasui, K., Yoshida, M., Yanagihara, K., Park, J-G., Nakamura, Y., and Inazawa, Y. CD44 is a potential target of amplification within the 11p13 amplicon detected in gastric cancer cell lines. Genes Chromosomes Cancer, 29: 315-324, 2000.
14. Imoto, I., Yang, Z. Q, Pimkhaokham, A., Tsuda, H., Shimada, Y., Imamura, M., Ohki, M., and Inazawa, J. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res., 61: 6629-6634, 2001.
15. Yasui, K., Arii, S., Zhao, C., Imoto, I., Ueda, M., Nagai, H., Emi, M., and Inazawa, J. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology, 35: 1476-1484, 2002.
16. Lastowska, M., Cotterill, S., Pearson, A. D. J., Roberts, P., McGuckin, A., Lewis, I., and Bown, N. Gain of chromosome arm 17q predicts unfavorable outcome in neuroblastoma patients. Eur. J. Cancer, 33: 1627-1633, 1997.
17. Wu, G. J., Sinclair, C. S., Paape, J., Ingle, J. N., Roche, P. C., James, C. D., and Couch, F. J. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res., 60: 5371-5375, 2000.
18. Barlund, M., Monni, O., Kononen, J., Cornelison, R., Torhorst, J., Sauter, G., Kallioniemi, O. P., and Kallioniemi, A. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res., 60: 5340-5344, 2000.
19. Wu, G. J., Sinclair, C., Hinson, S., Ingle, J. N., Roche, P. C., and Couch, F. J. Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors. Cancer Res., 61: 4951-4955, 2001.
20. Monni, O., Barlund, M., Mousses, S., Kononen, J., Sauter, G., Heiskanen, M., Paavola, P., Avela, K., Chen, Y., Bittner, M. L., and Kallioniemi. A. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc. Natl. Acad. Sci. USA, 98: 5711-5716, 2001.
21. Varis, A., Wolf, M., Monni, O., Vakkari, M. L., Kokkola, A., Moskaluk, C., Frierson, H., Jr., Powell, S. M., Knuutila, S., Kallioniemi, A., and El-Rifai, W. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res., 62: 2625- 2629, 2002.
22. Kaneko, M., Nishihira, H., Mugishima, H., Ohnuma, N., Nakada, K., Kawa, K., Fukuzawa, M., Suita, S., Sera, Y., and Tsuchida, Y. Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan. Med. Pediatr. Oncol., 31: 1-7, 1998.
23. Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B., and Brodeur, G. M. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N. Engl. J. Med., 328: 847-854, 1993.
24. Islam, A., Kageyama, H., Takada, N., Kawamoto, T., Takayasu, H., Isogai, E., Ohira, M., Hashizume, K., Kobayashi, H., Kaneko, Y., and Nakagawara, A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene, 19: 617-623, 2000.
25. Kallioniemi, A., Kallioniemi, O. P., Sudar, D., Rutovitz, D., Gray, J. W., Waldman, F., and Pinkel, D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Wash. DC), 258: 818-821, 1992.
26. Wittwer, C. T., Herrmann, M. G., Moss, A. A., and Rasmussen, R. P. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques, 22: 130-138, 1997.
27. Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., Buckner, J. C., and Jenkins, R. B. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst. (Bethesda), 93: 1246-1256, 2001.
28. Fleckenstein. D. S., Uphoff, C. C., Drexler, H. G., and Quentmeier, H. Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk. Res., 26: 207-214, 2002.
29. Carroll, J. S., Swarbrick, A., Musgrove, E. A., and Sutherland, R. L. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res., 62: 3126-3145, 2002.
30. Galderisi, U., Di Bernardo, G., Cipollaro, M., Peluso, G., Cascino, A., Cotrufo, R., and Melone, M. A. Differentiation and apoptosis of neuroblastoma cells: role of N-myc gene product. J. Cell. Biochem., 73: 97-105, 1999.
31. Janoueix-Lerosey, I., Penther, D., Thioux, M., de Cremoux, P., Derre, J., Ambros, P., Vielh, P., Benard, J., Aurias, A., and Delattre, O. Molecular analysis of chromosome arm 17q gain in neuroblastoma. Genes Chromosomes Cancer. 28: 276-284, 2000.
32. Lastowska, M., Cotterill, S., Bown, N., Cullinane, C., Variend, S., Lunec, J., Strachan, T., Pearson, A. D., and Jackson, M. S. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer. 34: 428-436, 2002.
33. Jacobs, J. J., Keblusek, P., Robanus-Maandag, E., Kristel, P., Lingbeek, M., Nederlof, P. M., van Welsem, T., van de Vijver, M. J., Koh, E. Y., Daley, G. Q., and van Lohuizen, M. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet., 26: 291-299, 2000.
34. Bulavin, D. V., Demidov, O. N., Saito, S., Kauraniemi, P., Phillips, C., Amundson, S. A., Ambrosino, C., Sauter, G., Nebreda, A. R., Anderson, C. W., Kallioniemi, A., Fornace, A. J., Appella, E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet., 31: 210-215, 2002.
35. Li, J., Yang, Y., Peng, Y., Austin, R. J., Van Eyndhoven, W. G., Nguyen, K. C., Gabriele, T., McCurrach, M. E., Marks, J. R., Hoey, T., Lowe, S. W., and Powers, S. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat. Genet., 31: 133-134, 2002.
36. Brinkschmidt, C., Poremba, C., Christiansen, H., Simon, R., Schafe, R. K. L., Terpe, H. J., Lampert, F., Boecker, W., and Dockhorn-Dworniczak, B. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. Br. J. Cancer, 77: 2223-2229, 1998.
37. Vettenranta, K., Aalto, Y., Wikstrom, S., Knuutila, S., and Saarinen-Pihkala, U. Comparative genomic hybridization reveals changes in DNA-copy number in poorrisk neuroblastoma. Cancer Genet. Cytogenet., 125: 125-130, 2001.
38. Plantaz, D., Vandesompele, J., Van Roy, N., Lastowska, M., Bown, N., Combaret, V., Favrot, M. C., Delattre, O., Michon, J., Benard, J., Hartmann, O., Nicholson, J. C., Ross, F. M., Brinkschmidt, C., Laureys, G., Caron, H., Matthay, K. K., Feuerstein, B. G., and Speleman, F. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int. J. Cancer, 91: 680-686, 2001.
39. Meddeb, M., Danglot, G., Chudoba, I., Venuat, A. M., Benard, J., Avet-Loiseau, H., Vasseur, B., Le Paslier, D., Terrier-Lacombe, M. J., Hartmann, O., and Bernheim, A. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer, 17: 156-165, 1996.
40. Hailat, N., Keim, D. R., Melhem, R. F., Zhu, X. X., Eckerskorn, C., Brodeur, G. M., Reynolds, C. P., Seeger, R. C., Lottspeich, F., Strahler, J. R., and Hanash, S. M. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc mye gene amplification. J. Clin. Investig., 88: 341-345, 1991.
41. Weber, R. G., Bostrom, J., Wolter, M., Baudis, M., Collins, V. P., Reifenberger, G., and Lichter, P. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc. Natl. Acad. Sci. USA. 94: 14719-14724, 1997.
42. Schmidt, H., Wurl, P., Taubert, H., Meye, A., Bache, M., Holzhausen, H. J., and Hinze, R. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer, 25: 205-211, 1999.
43. Fiscella, M., Zhang, H., Fan, S., Sakaguchi, K., Shen, S., Mercer. W. E., Vande Woude, G. F., O'Connor, P. M., and Appella, E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Nat. Acad. Sci. USA, 94: 6048-6053, 1997.
44. Choi, J., Appella, E., and Donehower, L. A. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol. Cell. Biol., 22: 1094-1105, 2002.